Stanford



Guido A. Davidzon

Clinical Associate Professor, Radiology - Rad/Nuclear Medicine

CLINICAL OFFICES

- **Nuclear Medicine**
  300 Pasteur Dr Rm H2200
  MC 5281
  Stanford, CA 94305
  Tel (650) 725-4711 **Fax** (650) 498-5047
- **Nuclear Medicine**
  300 Pasteur Dr Rm H0101
  MC 5281
  Stanford, CA 94305
  Tel (650) 725-4711 **Fax** (650) 498-5047

ACADEMIC CONTACT INFORMATION

- **Administrative Contact**
  Meke Fa'aoso - Administrative Assistant
  Email mfaaoso@stanford.edu
  Tel 650-497-5373

Bio

BIO

Dr. Guido A. Davidzon is a physician-scientist board certified in Nuclear Medicine. He is an attending physician in Nuclear Medicine and Molecular Imaging at Stanford Health Care. He graduated with honors from medical school in Argentina and completed an internship at Yale University New-Haven Hospital in Connecticut. He did his residency and was chief resident at Stanford Health Care. He completed a research fellowship in mitochondrial diseases at Columbia University in New York and, a U.S. National Library of Medicine Award supported, Biomedical Informatics fellowship at Massachusetts General Hospital in conjunction with a Science Masters at MIT.

Dr. Davidzon is a Clinical Associate Professor in the Department of Radiology at Stanford University. His clinical specialties include early diagnostic imaging of cancer, coronary artery disease, and dementias using molecular probes as well as the treatment of cancer for which he employs targeted radiopharmaceutical therapy.

At present, Dr. Davidzon is President of the Northern Chapter of the SNMMI. He is a faculty member at the Center for Artificial Intelligence in Medicine & Imaging and leads machine learning efforts for the Nuclear Medicine & Molecular Imaging Division. Dr. Davidzon steers the Cardiac Stress PET Clinical Program at Stanford that provides quantification of myocardial blood flow to assess epicardial and microvascular coronary circulation. He is the director of the DXA program at SHC and an active member of the Diversity Initiative Committee in Radiology. Dr. Davidzon is a native of Buenos Aires, Argentina, and has lived in the U.S. for over a decade.

CLINICAL FOCUS

- Nuclear Medicine
- Molecular Imaging

- Positron Emission Tomography
- Targeted Radionuclide Therapy

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Radiology - Rad/Nuclear Medicine

ADMINISTRATIVE APPOINTMENTS

- Interim Lead, Targeted Radionuclide Therapy Program, (2017-2018)
- Alt Member, Clinical Radiation Safety Committee, (2017- present)
- Director, DXA Imaging Program, (2017- present)
- Lead, Cardiac Stress PET Program, (2020- present)
- Lead, Machine Learning in NM & Molecular Imaging, (2020- present)

HONORS AND AWARDS

- First SNMMI Emerging Leader Award, SMMMI (6/2017)
- Future Leaders Academy Award, SNMMI (1/2015)
- Best Abstract Award Young Professionals Competition 2nd Sino-American Conference, SNMMI/CSNM (1/2013)
- Best Essay Travel Award, SNMMI/ACNM (1/2012)
- Nuclear Oncology Council Young Investigator Award, SNMMI (6/2011)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- President, SNMMI Northern California Chapter (2020 - present)
- Faculty, Stanford ADRC Imaging Core (2019 - present)
- Member, Center for Artificial Intelligence in Medicine & Imaging (2018 - present)
- Vice President, SNMMI Northern California Chapter (2018 - 2020)
- Member, Radiology Faculty Diversity Committee, Stanford University (2017 - present)
- Member, Prostate Cancer Outreach Working Group, SNMMI (2017 - 2019)
- Secretary/Treasurer, SNMMI Northern California Chapter (2016 - 2018)

PROFESSIONAL EDUCATION

- Board Certification: Nuclear Medicine, American Board of Nuclear Medicine (2013)
- Residency: Stanford Health Services - Fellowship/Diagnostic Radiology (2013) CA
- Fellowship, Massachusetts General Hospital - LCS , Clinical Informatics (2010)
- SM, Massachusetts Institute of Technology , Biomedical Informatics (2010)
- Internship: Yale - New Haven Hospital (2007) CT
- Fellowship, Columbia University , Mitochondrial Genetic Disorders (2006)
- MD with Honors, Universidad Maimonides, Argentina , Doctor in Medicine (2003)

Research & Scholarship

CLINICAL TRIALS

- [18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers, Recruiting
- A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer, Not Recruiting

- EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx, Not Recruiting
- Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT, Not Recruiting
- Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN), Not Recruiting

Publications

PUBLICATIONS

- **68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Moradi, F., Duan, H., Song, H., Davidzon, G. A., Chung, B. I., Thong, A. E., Loening, A. M., Ghanouni, P., Sonn, G., Iagaru, A.
  2022
- **Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up** *ONCOLOGIST*
  Duan, H., Ferri, V., Fisher, G., Shaheen, S., Davidzon, G., Iagaru, A., Aparici, C.
  2022
- **Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)**
  Duan, H., Song, H., Ferri, Fisher, G., Shaheen, S., Shah, J., Nguyen, J., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Mari, A. C.
  WILEY.2022: 141
- **Phenotypic Heterogeneity among GBA p.R202X Carriers in Lewy Body Spectrum Disorders.** *Biomedicines*
  Napolioni, V., Fredericks, C. A., Kim, Y., Channappa, D., Khan, R. R., Kim, L. H., Zafar, F., Couthouis, J., Davidzon, G. A., Mormino, E. C., Gitler, A. D., Montine, T. J., Schule, et al
  1800; 10 (1)
- **68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors.** *Translational oncology*
  Duan, H., Baratto, L., Hatami, N., Liang, T., Mari Aparici, C., Davidzon, G. A., Iagaru, A.
  2021; 15 (1): 101293
- **Six Recurrent Amyloid-Related Imaging Abnormality Episodes in a Patient Treated With Aducanumab.** *JAMA neurology*
  Hall, J. N., Mormino, E., Ng, A., Boumis, A., Gaudioso, J. L., Davidzon, G. A., Sha, S. J.
  2021
- **Author Correction: Low-count whole-body PET with deep learning in a multicenter and externally validated study.** *NPJ digital medicine*
  Chaudhari, A. S., Mittra, E., Davidzon, G. A., Gulaka, P., Gandhi, H., Brown, A., Zhang, T., Srinivas, S., Gong, E., Zaharchuk, G., Jadvar, H.
  2021; 4 (1): 139
- **A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Beinat, C., Patel, C. B., Haywood, T., Murty, S., Naya, L., Castillo, J. B., Reyes, S. T., Phillips, M., Buccino, P., Shen, B., Park, J. H., Koran, M. E., Alam, et al
  2021
- **A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy**
  Duan, H., Ghanouni, P., Hatami, N., Davidzon, G. A., Aparici, C., Thong, A., Sonn, G. A., Iagaru, A.
  SPRINGER.2021: S205-S206
- **PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES**
  Song, H., Nguyen, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2021: E1177-E1178
- **PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING**
  Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2021: E1178

- **A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer**
  Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G. A., Aparici, C., Thong, A., Sonn, G. A., Iagaru, A.
  SPRINGER.2021: S204
- **Low-count whole-body PET with deep learning in a multicenter and externally validated study.** *NPJ digital medicine*
  Chaudhari, A. S., Mittra, E., Davidzon, G. A., Gulaka, P., Gandhi, H., Brown, A., Zhang, T., Srinivas, S., Gong, E., Zaharchuk, G., Jadvar, H.
  2021; 4 (1): 127
- **Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors.** *Diagnostics (Basel, Switzerland)*
  Baratto, L., Toriihara, A., Hatami, N., Aparici, C. M., Davidzon, G., Levin, C. S., Iagaru, A.
  2021; 11 (6)
- **Initial Clinical Evaluation of [F-18]DASA-23, a PET Imaging Tracer for Evaluation of Aberrantly Expressed Pyruvate Kinase M2 in Glioblastoma**
  Beinat, C., Patel, C., Haywood, T., Naya, L., Castillo, J., Shen, B., Massoud, T., Iagaru, A., Davidzon, G., Recht, L., Gambhir, S.
  SOC NUCLEAR MEDICINE INC.2021
- **Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19**
  Zhang, R., Moradi, F., Aparici, C., Davidzon, G., Nguyen, J., Iagaru, A., Franc, B.
  SOC NUCLEAR MEDICINE INC.2021
- **A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer**
  Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G., Aparici, C., Moradi, F., Thong, A., Sonn, G., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2021
- **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al
  2021
- **Artificial Intelligence for Optimization and Interpretation of PET/CT and PET/MR Images.** *Seminars in nuclear medicine*
  Zaharchuk, G., Davidzon, G.
  2021; 51 (2): 134–42
- **Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)**
  Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.
  LIPPINCOTT WILLIAMS & WILKINS.2021: 456
- **Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
  Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.
  LIPPINCOTT WILLIAMS & WILKINS.2021: 456-457
- **Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
  Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., Franc, B., Iagaru, A., Aparici, C.
  LIPPINCOTT WILLIAMS & WILKINS.2021: 456
- **Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
  Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., Franc, B., Iagaru, A., Aparici, C.
  LIPPINCOTT WILLIAMS & WILKINS.2021: 456
- **Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)**
  Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.
  LIPPINCOTT WILLIAMS & WILKINS.2021: 456
- **Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience**
  Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., Franc, B., Iagaru, A., Aparici, C.
  LIPPINCOTT WILLIAMS & WILKINS.2021: 456-457
- **Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D. Y., Wong, J. Y., Pantel, A. R., Cho, S. Y., Gage, K. L., Piert, M. R., Iagaru, A., Pollard, et al

2021

- **Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*

  Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A., Franc, B. L.

  2021

- **A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)**

  Duan, H., Ferri, Fisher, G., Shaheen, S., Davidzon, G., Moradi, F., Nguyen, J., Franc, B., Iagaru, A., Mari, A. C.

  WILEY.2021: 181

- **A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma**

  Duan, H., Ferri, Fisher, G., Shaheen, S., Davidzon, G., Moradi, F., Nguyen, J., Franc, B., Iagaru, A., Mari, A. C.

  WILEY.2021: 180

- **The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.** *Molecular imaging and biology*

  Nakamoto, R. n., Harrison, C. n., Song, H. n., Guja, K. E., Hatami, N. n., Nguyen, J. n., Moradi, F. n., Franc, B. L., Aparici, C. M., Davidzon, G. n., Iagaru, A. n.

  2021

- **Increasing Diversity in Radiology and Molecular Imaging: Current Challenges.** *Molecular imaging and biology*

  Fite, B. Z., Hinostroza, V. n., States, L. n., Hicks-Nelson, A. n., Baratto, L. n., Kallianos, K. n., Codari, M. n., Yu, B. n., Jha, P. n., Shams, M. n., Stoyanova, T. n., Chapelin, F. F., Liu, et al

  2021

- **Multi-task weak supervision enables anatomically-resolved abnormality detection in whole-body FDG-PET/CT.** *Nature communications*

  Eyuboglu, S., Angus, G., Patel, B. N., Pareek, A., Davidzon, G., Long, J., Dunnmon, J., Lungren, M. P.

  2021; 12 (1): 1880

- **True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation.** *European journal of nuclear medicine and molecular imaging*

  Chen, K. T., Toueg, T. N., Koran, M. E., Davidzon, G. n., Zeineh, M. n., Holley, D. n., Gandhi, H. n., Halbert, K. n., Boumis, A. n., Kennedy, G. n., Mormino, E. n., Khalighi, M. n., Zaharchuk, et al

  2021

- **Association of CSF Biomarkers with Hippocampal-dependent Memory in Preclinical Alzheimer Disease.** *Neurology*

  Trelle, A. N., Carr, V. A., Wilson, E. N., Swarovski, M. S., Hunt, M. P., Toueg, T. N., Tran, T. T., Channappa, D. n., Corso, N. K., Thieu, M. K., Jayakumar, M. n., Nadiadwala, A. n., Guo, et al

  2021

- **Obituary for Sanjiv Sam Gambhir, MD, PhD.** *Clinical nuclear medicine*

  Davidzon, G., Franc, B., Mari Aparici, C., Moradi, F., Nguyen, J., Iagaru, A.

  2020

- **Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA**

  Duan, H., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G. A., Franc, B. L., Iagaru, A. H., Mari, C.

  SPRINGER.2020: S468–S469

- **Prospective Single Institution Study of F18-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: An Analysis of Lesions Detection and Localization**

  Iagaru, A., Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B., Nguyen, J., Moradi, F., Mari, C., Davidzon, G.

  SPRINGER.2020: S171

- **Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)**

  Duan, H., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G. A., Franc, B. L., Iagaru, A. H., Mari, C.

  SPRINGER.2020: S471–S472

- **Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy.** *Molecular imaging and biology*

Nakamoto, R., C Zaba, L., Rosenberg, J., Arani Reddy, S., W Nobashi, T., Ferri, V., Davidzon, G., Mari Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Lewis Franc, B.
2020

- **Application of Deep Learning to Predict Standardized Uptake Value Ratio and Amyloid Status on 18F-Florbetapir PET Using ADNI Data.** *AJNR. American journal of neuroradiology*
  Reith, F., Koran, M. E., Davidzon, G., Zaharchuk, G., Alzheimers Disease Neuroimaging Initiative
  2020
- **A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.**
  Baratto, L., Song, H., Duan, H., Aparici, C., Davidzon, G., Moradi, F., Srinivas, S., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2020
- **Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.**
  Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B., Moradi, F., Aparici, C., Davidzon, G., Srinivas, S., Iagaru, A.
  AMER SOC CLINICAL ONCOLOGY.2020
- **Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors**
  Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C., Iagaru, A., Davidzon, G.
  SOC NUCLEAR MEDICINE INC.2020
- **A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT**
  Duan, H., Hatami, N., Baratto, L., Davidzon, G., Aparici, C., Gambhir, S., Koglin, N., Witteles, R., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2020
- **Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer**
  Baratto, L., Duan, H., Hatami, N., Aparici, C., Davidzon, G., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2020
- **Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up**
  Moradi, F., Baratto, L., Duan, H., Hatami, N., Davidzon, G., Sonn, G., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2020
- **PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer**
  Baratto, L., Duan, H., Hatami, N., Song, H., Davidzon, G., Franc, B., Aparici, C., Moradi, F., Nguyen, J., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2020
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy**
  Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
  SOC NUCLEAR MEDICINE INC.2020
- **Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy**
  Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
  SOC NUCLEAR MEDICINE INC.2020
- **Visual Read Protocols for Clinicians Analyzing 18F-PI-2620 tau PET/MRI Images**
  Koran, M., Shams, S., Adams, P., Toueg, T., Azevedo, C., Hall, J., Corso, N., Sha, S., Fredericks, C., Greicius, M., Wagner, A., Zaharchuk, G., Davidzon, et al
  SOC NUCLEAR MEDICINE INC.2020
- **Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)**
  Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Aparici, C.
  SOC NUCLEAR MEDICINE INC.2020
- **INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING**
  Baratto, L., Song, H., Duan, H., Aparici, C., Hatami, N., Davidzon, G., Moradi, F., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2020: E1118

- **Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)**
  Duan, H., Girod, B., Ninatti, G., Ferri, Kunz, P., Fisher, G., Moradi, F., Davidzon, G., Franc, B., Lagaru, A., Aparici, M. C.
  KARGER.2020: 252

- **Extrahepatic 68Ga-DOTATATE-Avid Tumor Volume and Serum Chromogranin A Predict Short-Term Outcome of 177Lu-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors**
  Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, M. C., Lagaru, A., Davidzon, G.
  KARGER.2020: 274

- **Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation.** *Radiology case reports*
  Girod, B. J., Guja, K. E., Davidzon, G., Chan, F., Zucker, E., Franc, B. L., Moradi, F., Iagaru, A., Aparici, C. M.
  2020; 15 (2): 117–19

- **Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)**
  Duan, H., Ninatti, G., Girod, B., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Mari, C.
  AMER SOC CLINICAL ONCOLOGY.2020

- **Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin®) positron emission tomography.** *European journal of nuclear medicine and molecular imaging*
  Lee, J. J., Yang, H. n., Franc, B. L., Iagaru, A. n., Davidzon, G. A.
  2020

- **Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning.** *European journal of nuclear medicine and molecular imaging*
  Chen, K. T., Schürer, M. n., Ouyang, J. n., Koran, M. E., Davidzon, G. n., Mormino, E. n., Tiepolt, S. n., Hoffmann, K. T., Sabri, O. n., Zaharchuk, G. n., Barthel, H. n.
  2020

- **Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2.** *European journal of nuclear medicine and molecular imaging*
  Beinat, C. n., Patel, C. B., Haywood, T. n., Shen, B. n., Naya, L. n., Gandhi, H. n., Holley, D. n., Khalighi, M. n., Iagaru, A. n., Davidzon, G. n., Gambhir, S. S.
  2020

- **An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT.** *European journal of nuclear medicine and molecular imaging*
  Guja, K. E., Brown, R. n., Girod, B. n., Song, H. n., Harrison, C. n., Franc, B. L., Moradi, F. n., Davidzon, G. n., Iagaru, A. n., Aparici, C. M.
  2020

- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.** *European journal of nuclear medicine and molecular imaging*
  Nakamoto, R. n., Zaba, L. C., Rosenberg, J. n., Reddy, S. A., Nobashi, T. W., Davidzon, G. n., Aparici, C. M., Nguyen, J. n., Moradi, F. n., Iagaru, A. n., Franc, B. L.
  2020

- **Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases.** *European journal of nuclear medicine and molecular imaging*
  Mormino, E. C., Toueg, T. N., Azevedo, C. n., Castillo, J. B., Guo, W. n., Nadiadwala, A. n., Corso, N. K., Hall, J. N., Fan, A. n., Trelle, A. N., Harrison, M. B., Hunt, M. P., Sha, et al
  2020

- **Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., Moradi, F., Mari Aparici, C., Davidzon, G., Iagaru, A.
  2019

- **Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer**
  Iagaru, A., Baratto, L., Duan, H., Hatami, N., Mari, C., Davidzon, G.
  SPRINGER.2019: S277–S278

- **Prospective evaluation of F-18-DCFPyL in Patients with Biochemically Recurrent Prostate Cancer**
  Iagaru, A., Duan, H., Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G.
  SPRINGER.2019: S593

- **Machine Learning to Detect Prostate Cancer Recurrence using F-18-Fluciclovine PET**
  Davidzon, G. A., Lee, J., Yang, H., Song, H., Harrison, C., Iagaru, A.
  SPRINGER.2019: S65–S66

- **Bone Marrow and Tumor Radiomics at 18F-FDG PET/CT: Impact on Outcome Prediction in Non-Small Cell Lung Cancer.** *Radiology*
  Mattonen, S. A., Davidzon, G. A., Benson, J., Leung, A. N., Vasanawala, M., Horng, G., Shrager, J. B., Napel, S., Nair, V. S.
  2019: 190357

- **F-18-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma** *NUCLEAR MEDICINE AND MOLECULAR IMAGING*
  Laudicella, R., Davidzon, G., Vasanawala, S., Baldari, S., Iagaru, A.
  2019; 53 (4): 296–99

- **18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma.** *Nuclear medicine and molecular imaging*
  Laudicella, R., Davidzon, G., Vasanawala, S., Baldari, S., Iagaru, A.
  2019; 53 (4): 296-299

- **Non-invasive quantification of tau accumulation in dementia using simultaneous F-18-PI-2620 PET/MRI**
  Fan, A. P., Chen, K. T., Nadiadwala, A., Toueg, T., Sha, S., Greicius, M. D., Davidzon, G. A., Chin, F. T., Zaharchuk, G., Mormino, E. C.
  SAGE PUBLICATIONS INC.2019: 110–11

- **Preliminary Results of a Prospective Study of Ga-68-RM2 PET/MRI for Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging**
  Baratto, L., Duan, H., Harrison, C., Hatami, N., Aparici, C., Davidzon, G., Yohannan, T., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019

- **Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels**
  Harrison, C., Song, H., Franc, B. L., Guja, K., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019

- **Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer**
  Duan, H., Song, H., Baratto, L., Khalaf, M., Hatami, N., Franc, B., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019

- **Comparison of three interpretation criteria of Ga-68-PS A PET based on in er and intra-reader agreement**
  Toriihara, A., Nobashi, T., Baratto, L., Park, S., Hatami, N., Duan, H., Aparici, C., Davidzon, G., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019

- **Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer**
  Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019

- **[18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer.** *Tomography (Ann Arbor, Mich.)*
  Mattonen, S. A., Davidzon, G. A., Bakr, S., Echegaray, S., Leung, A. N., Vasanawala, M., Horng, G., Napel, S., Nair, V. S.
  2019; 5 (1): 145–53

- **[18F] FDG Positron Emission Tomography (PET) Tumor and Penumbra Imaging Features Predict Recurrence in Non-Small Cell Lung Cancer** *TOMOGRAPHY*
  Mattonen, S. A., Davidzon, G. A., Bakr, S., Echegaray, S., Leung, A. C., Vasanawala, M., Horng, G., Napel, S., Nair, V. S.
  2019; 5 (1): 145–53

- **Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans.** *Journal of digital imaging*
  Nobashi, T. n., Zacharias, C. n., Ellis, J. K., Ferri, V. n., Koran, M. E., Franc, B. L., Iagaru, A. n., Davidzon, G. A.
  2019

- **Initial experience with a PET/computed tomography system using silicon photomultiplier detectors.** *Nuclear medicine communications*
  Park, S. Y., Barrato, L. n., Hatami, N. n., Davidzon, G. n., Gambhir, S. S., Iagaru, A. n.
  2019

- **Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Toriihara, A. n., Nobashi, T. n., Baratto, L. n., Duan, H. n., Moradi, F. n., Park, S. n., Hatami, N. n., Aparici, C. n., Davidzon, G. n., Iagaru, A. n.
  2019
- **Integrated Bone Marrow and Tumor Radiomics on [18F] FDG Positron Emission Tomography (PET) Augment Stage for Outcome Prediction in Non-Small Cell Lung Cancer**
  Mattonen, S. A., Davidzon, G. A., Benson, J. A., Vasanawala, M., Leung, A. C., Horng, G. S., Shrager, J. B., Napel, S., Nair, V. S.
  AMER THORACIC SOC.2019
- **Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.** *European journal of nuclear medicine and molecular imaging*
  Toriihara, A. n., Baratto, L. n., Nobashi, T. n., Park, S. n., Hatami, N. n., Davidzon, G. n., Kunz, P. L., Iagaru, A. n.
  2019
- **Dual-Time Ga-68-RM2 Imaging for Staging Patients with Newly Diagnosed Intermediate or High Risk Prostate Cancer Using PMT and SiPM-Based Detectors PET/CT**
  Baratto, L., Duan, H., Hatami, N., Yohannan, T., Mari, C., Davidzon, G., Iagaru, A.
  SPRINGER.2018: S724
- **Ga-68-RM2 PET vs. Ga-68-PSMA-11 PET: Prospective Comparison in Patients with Biochemical Recurrence of Prostate Cancer**
  Baratto, L., Duan, H., Minamimoto, R., Mari, C., Yohannan, T., Davidzon, G., Iagaru, A.
  SPRINGER.2018: S151
- **Ga-68-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging**
  Baratto, L., Duan, H., Harrison, C., Mari, C., Davidzon, G., Yohannan, T., Iagaru, A.
  SPRINGER.2018: S151–S152
- **Ga-68-PSMA-11 Imaging for Biochemical Relapse of Prostate Cancer Using Dual-Time LYSO and SiPM-Based Detectors PET/CT**
  Duan, H., Park, S., Baratto, L., Hatami, N., Khalaf, M. H., Yohannan, T. K., Davidzon, G. A., Iagaru, A. H.
  SPRINGER.2018: S713
- **Embrace Progress** *JOURNAL OF NUCLEAR MEDICINE*
  Bradley, K. M., McGowan, D. R., Gleeson, F. V., Johnson, G. B., Young, J. R., Levin, C. S., Davidzon, G. A., Iagaru, A. H.
  2018; 59 (7): 1169
- **Prognostic value of volumetric parameters calculated from Ga-68-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors**
  Toriihara, A., Baratto, L., Nobashi, T., Park, S., Hatami, N., Davidzon, G., Kunz, P., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2018
- **Dual-Time Ga-68-PSMA-11 Imaging for Biochemically Recurrent Prostate Cancer Using LYSO and SiPM-Based Detectors PET/CT**
  Park, S., Hatami, N., Baratto, L., Yohannan, T., Davidzon, G., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2018
- **SiPM-based vs LYSO-based Ga-68-DOTA-TATE PET/CT: Comparison of Semi-Quantitative Measurements in Normal Tissues and Lesions**
  Baratto, L., Toriihara, A., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2018
- **Ga-68-RM2 PET/MRI Detection of Recurrent Prostate Cancer in Patients with Negative Conventional Imaging**
  Baratto, L., Harrison, C., Davidzon, G., Yohannan, T., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2018
- **Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality** *EJNMMI PHYSICS*
  Sonni, I., Baratto, L., Park, S., Hatami, N., Srinivas, S., Davidzon, G., Gambhir, S., Iagaru, A.
  2018; 5: 9
- **Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma** *CLINICAL NUCLEAR MEDICINE*
  Baratto, L., Davidzon, G. A., Moghbel, M., Hatami, N., Iagaru, A., Mittra, E. S.
  2018; 43 (1): 1–8

- **Positron Emission Tomography (PET) Tumor Penumbra Imaging Features Predict Outcome in Non-Small Cell Lung Cancer**
  Mattonen, S., Davidzon, G. A., Bakr, S., Vasanawala, M., Horng, G. S., Napel, S., Nair, V. S.
  AMER THORACIC SOC.2018
- **Initial Experience with a New PET/CT System Using SiPM Detectors**
  Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., Iagaru, A.
  SPRINGER.2017: S426
- **Improved Pulmonary Nodule Detection Using a Next Generation F-18-FDG PET Imaging System**
  Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Nair, V., Iagaru, A.
  SPRINGER.2017: S311-S312
- **SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions**
  Baratto, L., Park, S., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S. S., Iagaru, A.
  SPRINGER.2017: S431
- **First Experience with Fast Imaging Using Discovery MI PET/CT**
  Sonni, I., Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., Iagaru, A. H.
  SPRINGER.2017: S304
- **Initial Experience with a SiPM-based PET/CT Scanner: Influence of Acquisition Time on Image Quality**
  Sonni, I., Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2017
- **SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions**
  Baratto, L., Park, S., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2017
- **Initial Experience with a New PET/CT System Using SiPM Detectors: Image Quality Comparison with Standard PET/CT**
  Park, S., Baratto, L., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., Lagaru, A.
  SOC NUCLEAR MEDICINE INC.2017
- **18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT.** *PloS one*
  Baratto, L., Park, S. Y., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S. S., Iagaru, A.
  2017; 12 (6)
- **Bridging the Health Data Divide** *Journal of Medical Internet Research*
  Celi, L. A., Davidzon, G., et al
  2016; 18 (12)
- **Case 207: Hodgkin lymphoma with paraneoplastic hypercalcemic pancreatitis.** *Radiology*
  Mittra, E. S., Davidzon, G.
  2014; 272 (1): 296-300
- **NF-?B protein expression associates with (18)F-FDG PET tumor uptake in non-small cell lung cancer: A radiogenomics validation study to understand tumor metabolism.** *Lung cancer*
  Nair, V. S., Gevaert, O., Davidzon, G., Plevritis, S. K., West, R.
  2014; 83 (2): 189-196
- **Lung Fdg Uptake On Pet-CT Is Decreased In Patients With COPD**
  Nair, V. S., Guo, H., Davidzon, G., Zirlinger, A., Chooljian, D. M., Mittra, E., Rubin, D.
  AMER THORACIC SOC.2014
- **Pilot Prospective Evaluation of Early Response to Bevacizumab Treatment Using the Novel PET/CT Radiopharmaceutical 18F FPPRGD2**
  Iagaru, A., Mosci, C., Davidzon, G., Kumar, M., Shen, B., Chin, F., Gambhir, S. S.
  SPRINGER.2013: S185
- **Biodistribution and kinetics of 18F FPPRGD2 in cancer patients**
  Davidzon, G., Mosci, C., Mittra, E., Shen, B., Chin, F., Gambhir, S., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2013

- **Biodistribution and kinetics of 18F FPPRGD2 in cancer patients** *SNMMI*
  Davidzon, G., Mosci, C., MIttra, E., Shen, B., Chin, F., Gambhir, S., Iagaru, A.
  J Nucl Med.2013

- **FDG-PET/CT Initial and Subsequent Therapy Evaluation: Progressing to PET/MR Imaging.** *PET clinics*
  Mosci, C., Davidzon, G. A., Quon, A.
  2012; 7 (4): 369-380

- **A Database-driven Decision Support System: Customized Mortality Prediction.** *Journal of personalized medicine*
  Celi, L. A., Galvin, S., Davidzon, G., Lee, J., Scott, D., Mark, R.
  2012; 2 (4): 138-148

- **Prognostic PET F-18-FDG Uptake Imaging Features Are Associated with Major Oncogenomic Alterations in Patients with Resected Non-Small Cell Lung Cancer** *CANCER RESEARCH*
  Nair, V. S., Gevaert, O., Davidzon, G., Napel, S., Graves, E. E., Hoang, C. D., Shrager, J. B., Quon, A., Rubin, D. L., Plevritis, S. K.
  2012; 72 (15): 3725-3734

- **Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms**
  Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2012

- **Detection of bone marrow disease in lymphoma using computer aided segmentation and analysis**
  Davidzon, G., Peng, Z., Anand, V., Zhou, X., Quon, A.
  SOC NUCLEAR MEDICINE INC.2012

- **Utility of 18F FDG PET/CT in patients with advanced thymic neoplasms** *SNMMI*
  Davidzon, G., Wakelee, H., Neal, J., Mittra, E., Quon, A., Iagaru, A.
  J Nucl Med.2012

- **Detection of bone marrow disease in lymphoma using computer aided segmentation and analysis** *SNMMI*
  Davidzon, G., Peng, Z., Anand, V., Zhou, X., Quon, A.
  J Nucl Med.2012

- **Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT**
  Davidzon, G., Mittra, E.
  SOC NUCLEAR MEDICINE INC.2011

- **A Clinical Database-Driven Approach to Decision Support: Predicting Mortality Among Patients with Acute Kidney Injury** *JOURNAL OF HEALTHCARE ENGINEERING*
  Celi, L. A., Tang, R. J., Villarroel, M. C., Davidzon, G. A., Lester, W. T., Chueh, H. C.
  2011; 2 (1): 97-109

- **Comparison of four different imaging response criteria in patients with Hodgkin and non-Hodgkin lymphoma using PET/CT** *SNMMI*
  Davidzon, G., Mittra, E.
  J Nucl Med.2011

- **Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene** *NEUROMUSCULAR DISORDERS*
  Akman, H. O., Davidzon, G., Tanji, K., MacDermott, E. J., Larsen, L., Davidson, M. M., Haller, R. G., Szczepaniak, L. S., Lehman, T. J., Hirano, M., DiMauro, S.
  2010; 20 (6): 397-402

- **Intracerebral Periventricular Pseudocysts in a Fetus with Mitochondrial Depletion Syndrome: An Association or Coincidence** *FETAL DIAGNOSIS AND THERAPY*
  Rohrbach, M., Chitayat, D., Maegawa, G., Shanske, S., Davidzon, G., Chong, K., Clarke, J. T., Toi, A., Tarnopolsky, M., Robinson, B., Blaser, S.
  2009; 25 (2): 177-182

- **Autosomal dominant psychiatric disorders and mitochondrial DNA multiple deletions: Report of a family** *JOURNAL OF AFFECTIVE DISORDERS*
  Mancuso, M., Ricci, G., Choub, A., Filosto, M., DiMauro, S., Davidzon, G., Tessa, A., Santorelli, F. M., Murri, L., Siciliano, G.
  2008; 106 (1-2): 173-177

- **Progressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in POLG2 and OPA1** *ARCHIVES OF NEUROLOGY*

Ferraris, S., Clark, S., Garelli, E., Davidzon, G., Moore, S. A., Kardon, R. H., Bienstock, R. J., Longley, M. J., Mancuso, M., Rios, P. G., Hirano, M., Copeland, W. C., DiMauro, et al
2008; 65 (1): 125-131

- **SemanticDx: a prototype to facilitate use of biostatistics at the point-of-care.** *AMIA ... Annual Symposium proceedings / AMIA Symposium. AMIA Symposium*
  Davidzon, G., Pankey, E., Loudon, T., Schmid, P., Berger, B., Berkowicz, D.
  2008: 921-?
- **Juvenile Alpers disease** *ARCHIVES OF NEUROLOGY*
  Wiltshire, E., Davidzon, G., DiMauro, S., Akman, H. O., Sadleir, L., Haas, L., Zuccollo, J., McEwen, A., Thorburn, D. R.
  2008; 65 (1): 121-124
- **Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders** *EUROPEAN JOURNAL OF HUMAN GENETICS*
  Hakonen, A. H., Davidzon, G., Salemi, R., Bindoff, L. A., Van Goethem, G., DiMauro, S., Thorburn, D. R., Suomalainen, A.
  2007; 15 (7): 779-783
- **Severe encephalomyopathy in a patient with homoplasmic A5814G point mutation in mitochondrial tRNA(Cys) gene** *NEUROMUSCULAR DISORDERS*
  Scuderi, C., Borgione, E., Musumeci, S., Elia, M., Castello, F., Fichera, M., Davidzon, G., DiMauro, S.
  2007; 17 (3): 258-261
- **Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene** *ARCHIVES OF NEUROLOGY*
  Oskoui, M., Davidzon, G., Pascual, J., Erazo, R., Gurgel-Giannetti, J., Krishna, S., Bonilla, E., De Vivo, D. C., Shanske, S., DiMauro, S.
  2006; 63 (8): 1122-1126
- **A polymorphic polymerase** *BRAIN*
  DiMauro, S., Davidzon, G., Hirano, M.
  2006; 129: 1637-1639
- **Early-onset familial Parkinsonism due to POLG mutations** *ANNALS OF NEUROLOGY*
  Davidzon, G., Greene, P., Mancuso, M., Klos, K. J., Ahlskog, J. E., Hirano, M., DiMauro, S.
  2006; 59 (5): 859-862
- **L/I-13 Donor hepatectomy morbidity based on the Clavien scale** *Clinical Transplantation*
  Kinkhabwala, M., Davidzon, G., Lapointe, R., Brown, R., Emond, J.
  2006; 20: 31-32
- **POLG mutations and Alpers syndrome** *ANNALS OF NEUROLOGY*
  Davidzon, G., Mancuso, M., Ferraris, S., Quinzii, C., Hirano, M., Peters, H. L., Kirby, D., Thorburn, D. R., DiMauro, S.
  2005; 57 (6): 921-923
- **Hereditary ferritinopathy: A novel mutation, its cellular pathology, and pathogenetic insights** *JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY*
  Mancuso, M., Davidzon, G., Kurlan, R. M., Tawil, R., Bonilla, E., Di Mauro, S., Powers, J. M.
  2005; 64 (4): 280-294
- **Mitochondrial DNA and disease** *ANNALS OF MEDICINE*
  DiMauro, S., Davidzon, G.
  2005; 37 (3): 222-232
- **A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F] F-AraG**
  Colevas, D. A., Davidzon, G. A., Sunwoo, J. B., et al
  2018